Cardioembolic stroke

American Journal of Medicine

Volumn 100, Issue 4, 1996, Pages 465-474

  Brickner, M Elizabeth ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ANTICOAGULATION; AORTA ATHEROSCLEROSIS; AORTA STENOSIS; BACTERIAL ENDOCARDITIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE CONTROL; ECHOCARDIOGRAPHY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART ATRIUM SEPTUM DEFECT; HEART DILATATION; HEART DISEASE; HEART INFARCTION; HEART TUMOR; HUMAN; MITRAL VALVE PROLAPSE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; RHEUMATIC HEART DISEASE; STROKE;

EID: 0030008009     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)89525-3     Document Type: Review

References (92)

1. American Heart Association. Heart and stroke facts: 1991 statistical supplement. Dallas, Texas: American Heart Association; 1992
2. Caplan LR. Diagnosis and treatment of ischemic stroke. JAMA. 1991;266:2413-2418.
3. Cerebral Embolism Task Force. Report on cardiogenic brain embolism. Arch Neurol. 1986;43:71-84.
4. Foulkes MA, Wolf PA, Price TR, et al. The Stroke Data Bank: design, methods, and baseline characteristics. Stroke. 1988; 19:547-554.
5. Cerebral Embolism Task Force. Cardiogenic brain embolism: the second report of the cerebral embolism task force. Arch Neurol. 1989;46:727-743.
6. Mohr JP, Caplan LR, Melski JW, et al. The Harvard Cooperative Stroke Registry: a prospective registry. Neurology. 1978;28:754-762.
7. Wolf PA, Kannel W, McGee DL, et al. Duration of atrial fibrillation and imminence of stroke: the Framingham Study. Stroke. 1983;14:664-667.
8. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28:973-977.
9. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation: a population-based study over three decades. NEJW. 1987;317: 669-674.
10. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30-year follow up in the Framingham study. JAMA. 1985;254:3449-3453.
11. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. Arch Intern Med. 1987;147:1561-1564.
12. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. NEJIW. 1990;323:1505-1511.
13. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation. 1991:84:527-539.
14. Petersen P, Godtfredsen J. Embolic complications in paroxysmal atrial fibrillation. Stroke. 1986;17:622-626.
15. Roy D, Marchand E, Gagne P, et al. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J. 1986;112:1039-1043.
16. Petersen P, Boysen G, Godfredsen J, et al. Placebo-controlled randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet. 1989;1:175-179.
17. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. NEJM. 1992;327: 1406-1412.
18. Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anti-coagulation (CAFA) study. J Am Coll Cardiol. 1991; 18:349-355.
19. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
20. Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest. 1992;4:426S-433S.
21. Sage JI, Van Uitert RL. Risk of recurrent stroke in patients with atrial fibrillation and non-valvular heart disease. Stroke. 1983;14:537-540.
22. Wood P. Diseases of the Heart and Circulation. Philadelphia: JB Lippincott Co.; 1956.
23. Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. BMJ. 1964;1:209-212.
24. Levine HJ, Pauker SG, Salzman EW, Eckman MH. Antithrombotic therapy in valvular heart disease. Chest. 1992;4:434S-444S.
25. Cairns JA, Hirsh J, Lewis HD, et al. Antithrombotic agents in coronary artery disease. Chest. 1992;4:456S-481S.
26. Bodenheimer MM, Sauer D, Shareef B, et al. Relation between myocardial infarct location and stroke. J Am Coll Cardiol. 1994;24:61-66.
27. Sloan MA, Plotnick GD. Stroke complicating thrombolytic therapy of acute myocardial infarction. J Am Coll Cardiol. 1990;16:541-544.
28. Maggioni AP, Franzosi MG, Santoro E, et al. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. NEJM. 1992;327:1-6.
29. Komrad MS, Coffey CE, Coffey MS, et al. Myocardial infarction and stroke. Neurology. 1984;34:1403-1409.
30. Keren A, Goldberg S, Gottlieb S, et al. Natural history of left ventricular thrombi: their appearance and resolution in the posthospitalization period of acute myocardial infarction. J Am Coll Cardiol. 1990; 15:790-800.
31. Turpie AGG, Robinson JG, Doyle DJ, et al. Comparison of high dose with low-dose subcutaneous heparin to prevent left ventricular wall mural thrombus in patients with acute transmural anterior myocardial infarction. NEJM. 1989; 320:352-357.
32. Medalie JH, Goldbourt U. Unrecognized myocardial infarction: five-year incidence, mortality, and risk factors. Ann Intern Med. 1976;84:526-531.
33. Meltzer RS, Visser CA, Fuster V. Intracardiac thrombi and systemic embolization. Ann Intern Med. 1986;104:689-698.
34. Lapeyre AC, Steele PM, Kazmier FJ, et al. Systemic embolism in chronic left ventricular aneurysm: incidence and the role of anticoagulation. J Am Coll Cardiol. 1985;6:534-538.
35. Gottdiener JS, Gay JA, Van Voorhees LL, et al. Frequency and embolic potential of left ventricular thrombus in dilated cardiomyopathy: assessment by two dimensional echocardiography. Am J Cardiol. 1983;52:1281-1285.
36. Fuster V, Gersh BJ, Giuliana ER, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 1981;47:525-531.
37. Katz SD, Marantz PR, Biasucci L, et al. Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am Heart J. 1993;126:141-146.
38. Dunkman WB, Johnson GR, Cohn JN. Incidence of thromboembolic events in congestive heart failure: the V-HeFT study. Circulation. 1988;78(suppl II);II-617. Abstract.
39. Falk RH, Pollak A, Tandon PK, Packer M. The effect of warfarin on prevalence of stroke in patients with severe heart failure. J Am Coll Cardiol. 1993;21:218A. Abstract.
40. Stratton JR, Resnick AD. Increased embolic risk in patients with left ventricular thrombi. Circulation. 1987;75:1003-1011.
41. Stratton JR, Nemanich JW, Johannessen KA, Resnick AD. Fate of left ventricular thrombi in patients with remote myocardial infarction or idiopathic cardiomyopathy. Circulation. 1988;78:1388-1393.
42. Israel DH, Sharma SK, Fuster V. Antithrombotic therapy in prosthetic heart valve replacement. Am Heart J. 1994;127:400-411.
43. Grunkemeier GL, Rahimtoola SH. Artificial heart valves. Annual Rev Med. 1990;41:251-263.
44. Edmunds LH Jr. Thromboembolic complications of current cardiac valvular prostheses. Ann Thorac Surg. 1982;34:96-106.
45. Stein PD, Alpert JS, Copeland J, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 1992;102: 445S-455S.
46. Saour JN, Sieck JO, Mamo LAR, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. NEJM. 1990;322; 428-432.
47. Turpie AGG, Gunstensen J, Hirsh J, et al. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet. 1988;1:1242-1245.
48. Turpie AGG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. NEJM. 1993;329:524-529.
49. Hayashi J, Nakazawa S, Oguma F, et al. Combined warfarin and antiplatelet therapy after St. Jude Medical valve replacement for mitral valve disease. J Am Coll Cardiol. 1994;23:672-677.
50. Levine RA, Stathogianni E, Newell JB, et al. Reconsideration of echocardiographic standards for mitral valve prolapse: lack of association between leaflet displacement isolated to the apical four chamber view and independent echocardiographic evidence of abnormality. J Am Coll Cardiol. 1988;11:1010-1019.
51. Marks AR, Choong CY, Sanfilippo AJ, et al. Identification of high-risk and low-risk subgroups of patients with mitral-valve prolapse. NEJM. 1989;320:1031-1036.
52. Nishimura RA, McGood MD, Shub C, et al. Echocardiographically documented mitral-valve prolapse. NEJM. 1985;313:1305-1309.
53. Boughner DR, Barnett HJM. The enigma of the risk of stroke in mitral valve prolapse Stroke. 1985;16:175-177. Editorial.
54. Tunick PA, Perez JL, Kronzon I. Protruding atheromas in the thoracic aorta and systemic embolization. Ann Intern Med. 1991;115:423-427.
55. Amarenco P, Duyckaerts C, Tzourio C, et al. The prevalence of ulcerated plaques in the aortic arch in patient with stroke. NEJM. 1992;326:221-225.
56. Amarenco P, Cohen A, Tzourio C, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. NEJM. 1994;331:1474-1479.
57. Belkin RN, Kisslo J. Atrial septal aneurysm: recognition and clinical relevance. Am Heart J. 1990:120:948-957.
58. Pearson AC, Nagelhout D, Castello R, et al. Atrial septal aneurysm and stroke: a transesophageal echocardiographic study. J Am Coll Cardiol. 1991;18:1223-1229.
59. Belkin RN, Hurwitz BJ, Kisslo J. Atrial septal aneurysm: association with cerebrovascular and peripheral embolic events. Stroke. 1987;18:856-862.
60. Schneider B, Hanrath P, Vogel P, Meinertz T. Improved morphologic characterization of atrial septal aneurysm by transesophageal echocardiography: relation to cerebrovascular events. J Am Coll Cardiol. 1990; 16:1000-1009.
61. Thompson T, Evans W. Paradoxical embolism. Q J Med. 1930;23: 135-150.
62. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clinic Proc. 1984;59:17-20.
63. Lechat P, Mas JL, Lascault G, et al. Prevalence of patent foramen ovale in patients with stroke. NEJM. 1988;318:1148-1152.
64. Webster MWI, Smith HJ, Sharpe DN, et al. Patent foramen ovale in young stroke patients. Lancet. 1988;2:11-12.
65. deBelder MA. Stroke due to patent foramen ovale. In: Hurst JW. New Types of Cardiovascular Diseases. New York: Igaku-Shoin; 1994: 113-127.
66. Di Tullio M, Sacco RL, Gopal A, et al. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med. 1992;117:461-465.
67. de Beider MA, Tourikis L, Leech G, et al. Risk of patent foramen ovale for thromboembolic events in all age groups. Am J Cardiol. 1992;69: 1316-1320.
68. Zhu WX, Khanderia BK, Click RL, et al. Patent foramen ovale detected by contrast transesophageal echo: a lack of association with systemic embolic events Circulation. 1991;84:II-694. Abstract.
69. Stollberger C, Slany J, Schuster I, et al. The prevalence of deep venous thrombosis in patients with suspected paradoxical embolism. Ann Intern Med. 1993;119:461-465.
70. Merino A, Hauptman P, Badimon L, et al. Echocardiographic "smoke" is produced by an interaction of erythrocytes and plasma proteins modulated by shear forces. J Am Coll Cardiol. 1992;20:1661-1668.
71. Black IW, Hopkins AP, Lee LCL, Walsh WF. Left atrial spontaneous echo contrast: a clinical and echocardiographic analysis. J Am Coll Cardiol. 1991; 18:398-404.
72. Mikell FL, Asinger RW, Elsperger KJ, et al. Regional stasis of blood in the dysfunctional left ventricle: echocardiographic detection and differentiation from early thrombosis. Circulation. 1982;66:755-763.
73. Daniel WG, Nellessen U, Schroder E, et al. Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk. J Am Coll Cardiol. 1988;11:1204-1211.
74. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol. 1994;23:961-969.
75. Zabalgoita M, Gandhi DK, McPherson DD, et al. Spontaneous echo contrast in severe left ventricular dysfunction: a risk factor for thromboembolism. Circulation. 1990;82:III-109. Abstract.
76. Sigel B, Coelho JCU, Spigos DG, et al. Ultrasonography of blood during stasis and coagulation. Invest Radiol. 1981;16:71-76.
77. Salgado AV, Furlan AJ, Keys TF, et al. Neurological complications of native and prosthetic valve endocarditis: a 12-year experience. Neurology. 1989;39:173-178.
78. Paschalis C, Pugsley W, John R, et al. Rate of cerebral embolic events in relation to antibiotic therapy and anticoagulant therapy in patients with bacterial endocarditis. Eur Neurol. 1990;30:87-89.
79. Kanis JA. The use of anticoagulants in bacterial endocarditis. Postgrad Med J. 1974;50:312-313.
80. Wilson WR, Geraci JE, Danielson GK, et al. Anticoagulant therapy and central nervous system complications in patients with prosthetic valve endocarditis. Circulation. 1978;57:1004-1007.
81. Carpenter JL, McAllister CK. Anticoagulation in prosthetic valve endocarditis. South Med J. 1983;76:1372-1375.
82. Lopez JA, Ross RS, Fishbein MC, Siegel RJ. Nonbacterial thrombotic endocarditis: a review. Am Heart J. 1987;113:773-784.
83. Rogers LR, Cho ES, Kempin S, Posner JB. Cerebral infarction from nonbacterial thrombotic endocarditis: clinical and pathological study including the effects of anticoagulation. Am J Med. 1987;83:746-756.
84. Fulkerson PK, Beaver BM, Auseon JC, Graber HL. Calcification of the mitral annulus: etiology, clinical associations, complications and therapy. Am J Med. 1979;66:967-977.
85. Benjamin EJ, Plehn JF, D'Agostino RB, et al. Mitral annular calcification and the risk of stroke in an elderly cohort. NEJM. 1992;327:374-379.
86. Lombard JT, Selzer A. Valvular aortic stenosis. Ann Intern Med. 1987;106: 292-298.
87. Davidson CJ, Skelton TN, Kisslo KB, et al. The risk of systemic embolization associated with percutaneous balloon valvuloplasty in adults. Ann Intern Med. 1988;108:557-560.
88. Brickner ME, Friedman DB, Cigarroa CG, Grayburn PA. Relation of thrombus in the left atrial appendage by transesophageal echocardiography to clinical risk factors for thrombus formation. Am J Cardiol. 1994;74: 391-393.
89. Lovett JL, Sandok BA, Guiliani ER, Nasser FN. Two-dimensional echocardiography in patients with focal cerebral ischemia. Ann Intern Med. 1981;95:14.
90. ACC/AHA Task Force. ACC/AHA guideline for the clinical application of echocardiography. J Am Coll Cardiol. 1990;16:1505-1528.
91. DeRook FA, Comess KA, Albers GW, Popp RL. Transesophageal echocardiography in the evaluation of stroke. Ann Intern Med. 1992;117: 922-932.
92. Pearson AC, Labovitz AJ, Tatineni S, Gomez CR. Superiority of transesophageai echocardiography in detecting cardiac source of embolism in patients with cerebral ischemia of uncertain etiology. J Am Coll Cardiol. 1991; 17:66-72.